Clinical uses of intravenous immunoglobulin in pregnancy.
The obstetric literature contains numerous reports of IVIG therapy for various conditions encountered during pregnancy. The mechanisms of action of IVIG are uncertain and may vary depending on the specific disorder. Immunoglobulin G infusions appear to be well tolerated by the parturient. The occurrence of major and minor side effects is uncommon, and infectious morbidity is low. Further research will be necessary to elucidate the specific mechanisms of action of IVIG in certain disease states. Determining the exact "therapeutic agent" in IVIG for each specific disease state may allow for a more tailored approach to treatment (i.e., isolation or production of the particular antibody). Outcome assessment, long-term positive and negative effects, cost-benefit analysis, and effects on fetal and neonatal immune function require further study through randomized trials.
Clark
A L
AL
Department of Obstetrics and Gynecology, University of Louisville, KY 40292, USA.
D016736:Antiphospholipid Syndrome / Q000628:therapy*; D005260:Female; D006327:Heart Block / Q000151:congenital / Q000628:therapy; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007231:Infant, Newborn; D010976:Platelet Count; D011247:Pregnancy; D011248:Pregnancy Complications / Q000628:therapy*; D011250:Pregnancy Complications, Hematologic / Q000628:therapy; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000503:physiopathology / Q000628:therapy*; D012203:Rh Isoimmunization; D016896:Treatment Outcome
D016756:Immunoglobulins, Intravenous